Canadian Journal of Cardiology
Point/Counterpoint| Volume 31, ISSUE 5, P596-600, May 2015

The Metabolic Syndrome Is an Important Concept in Therapeutic Decision-Making

Published:November 05, 2014DOI:


      Traditional risk factors can underestimate the true risk of developing atherosclerotic cardiovascular disease. Abdominal obesity is associated with a cluster of risk factors that include dyslipidemia, dysglycemia, and hypertension, termed metabolic syndrome (MS). The presence of MS increases cardiovascular risk 50%-100% beyond that defined according to traditional risk factors, and increases the risk of developing type 2 diabetes. Recognition of patients with MS is important to: (1) identify patients at increased risk beyond that conveyed by traditional risk factors; and (2) understand that the metabolic abnormalities associated with MS are largely reversed by measures that reduce abdominal obesity.


      Les facteurs de risque traditionnels peuvent sous-estimer le risque réel de développement de maladies cardiovasculaires athérosclérotiques. L’obésité abdominale est associée à un ensemble de facteurs de risque comprenant la dyslipidémie, la dysglycémie et l’hypertension que l’on nomme le syndrome métabolique (SM). La présence du SM accroît le risque cardiovasculaire de 50 % à 100 % au-delà de celui qui est défini en fonction des facteurs de risque traditionnels, et accroît le risque de développement du diabète de type 2. La détection des patients souffrant du SM est importante pour : 1) déterminer les patients exposés à un risque élevé au-delà du risque transmis par les facteurs de risque traditionnels; 2) comprendre que les anomalies métaboliques associées au SM se résorbent en grande partie grâce aux mesures qui réduisent l’obésité abdominale.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • D’Agostino Sr., R.B.
        • Vasan R.S.
        • Pencina M.J.
        • et al.
        General cardiovascular risk profile for use in primary care: the Framingham Heart study.
        Circulation. 2008; 117: 743-753
        • Yusuf S.
        • Hawken S.
        • Ounpuu S.
        • et al.
        Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart study): case-control study.
        Lancet. 2004; 364: 937-952
        • Mente A.
        • Yusuf S.
        • Islam S.
        • et al.
        Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries.
        J Am Coll Cardiol. 2010; 55: 2390-2398
        • Cardiometabolic Risk Working Group
        • Leiter L.A.
        • Fitchett D.H.
        • et al.
        Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary).
        Can J Cardiol. 2011; 27: e1-33
        • Alberti K.G.
        • Zimmet P.Z.
        Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.
        Diabet Med. 1998; 15: 539-553
        • Grundy S.M.
        • Brewer Jr., H.B.
        • Cleeman J.I.
        • et al.
        Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.
        Arterioscler Thromb Vasc Biol. 2004; 24: e13-e18
        • Alberti K.G.
        • Zimmet P.
        • Shaw J.
        Metabolic syndrome–a new world-wide definition. A consensus statement from the International Diabetes Federation.
        Diabet Med. 2006; 23: 469-480
        • Lemieux I.
        • Poirier P.
        • Bergeron J.
        • et al.
        Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology?.
        Can J Cardiol. 2007; 23: 23B-31B
        • Despres J.P.
        • Lemieux I.
        • Bergeron J.
        • et al.
        Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.
        Arterioscler Thromb Vasc Biol. 2008; 28: 1039-1049
        • Lamarche B.
        • Tchernof A.
        • Mauriege P.
        • et al.
        Fasting insulin and apolipoprotein b levels and low-density lipoprotein particle size as risk factors for ischemic heart disease.
        JAMA. 1998; 279: 1955-1961
        • Ford E.S.
        • Giles W.H.
        • Dietz W.H.
        Prevalence of the metabolic syndrome among us adults: findings from the third National Health and Nutrition Examination Survey.
        JAMA. 2002; 287: 356-359
        • Beltran-Sanchez H.
        • Harhay M.O.
        • Harhay M.M.
        • McElligott S.
        Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010.
        J Am Coll Cardiol. 2013; 62: 697-703
        • Galassi A.
        • Reynolds K.
        • He J.
        Metabolic syndrome and risk of cardiovascular disease: a meta-analysis.
        Am J Med. 2006; 119: 812-819
        • Gami A.S.
        • Witt B.J.
        • Howard D.E.
        • et al.
        Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies.
        J Am Coll Cardiol. 2007; 49: 403-414
        • Daly C.A.
        • Hildebrandt P.
        • Bertrand M.
        • et al.
        Adverse prognosis associated with the metabolic syndrome in established coronary artery disease: data from the EUROPA trial.
        Heart. 2007; 93: 1406-1411
        • de Simone G.
        • Devereux R.B.
        • Chinali M.
        • et al.
        Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study.
        Diabetes Care. 2007; 30: 1851-1856
        • Noto D.
        • Barbagallo C.M.
        • Cefalu A.B.
        • et al.
        The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population.
        Atherosclerosis. 2008; 197: 147-153
        • Kahn R.
        • Buse J.
        • Ferrannini E.
        • et al.
        The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.
        Diabetes Care. 2005; 28: 2289-2304
        • Sattar N.
        • Gaw A.
        • Scherbakova O.
        • et al.
        Metabolic syndrome with and without c-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.
        Circulation. 2003; 108: 414-419
        • Fitchett D.H.
        • Mancini G.B.
        • Gregoire J.
        • Anderson T.
        • McPherson R.
        Risk stratification and selection for statin therapy: going beyond Framingham.
        Can J Cardiol. 2014; 30: 667-670
        • Hirsso P.K.
        • Timonen M.J.
        • Jokelainen J.J.
        • et al.
        Association between high-sensitive measurement of c-reactive protein and metabolic syndrome as defined by International Diabetes Federation, National Cholesterol Education Program, and World Health Organization criteria in a population-based cohort of 55-year-old Finnish individuals.
        Diabetes Care. 2006; 29: 2177-2178
        • Devaraj S.
        • Singh U.
        • Jialal I.
        Human c-reactive protein and the metabolic syndrome.
        Curr Opin Lipidol. 2009; 20: 182-189
        • Ridker P.M.
        • Buring J.E.
        • Cook N.R.
        • Rifai N.
        C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women.
        Circulation. 2003; 107: 391-397
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.
        • et al.
        Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
        • Teoh H.
        • Despres J.P.
        • Dufour R.
        • et al.
        Identification and management of patients at elevated cardiometabolic risk in Canadian primary care: how well are we doing?.
        Can J Cardiol. 2013; 29: 960-968